Specifically for neuroblastoma numerous studies have shown that targeting the PI3K/AKT/mTOR signaling pathway is a valid treatment option for aggressive neuroblastoma and decreased proliferation in vitro and reduced tumor growth in vivo17-19,41,42,45-48. This evidence concerns the gene MTOR and neuroblastoma.